智通财经网·2025-08-21 13:33Core Viewpoint - Dynavax Technologies (DVAX.US) shares rose approximately 7% following the announcement that its investigational shingles vaccine Z-1018 elicited an immune response comparable to GlaxoSmithKline's (GSK.US) Shingrix vaccine in Phase I/II trials [1] Group 1: Clinical Trial Results - The top-line data from the first part of the clinical trial indicated that Z-1018 achieved an overall vaccine response rate of 89.7%, while Shingrix had a response rate of 90.3% [1] - The study aimed to evaluate the effectiveness of Z-1018 compared to Shingrix in individuals aged 50 to 69 years [1] - Z-1018 demonstrated favorable tolerability and safety characteristics [1] Group 2: Adverse Reactions - Among participants receiving Z-1018, 12.5% experienced grade 2 or 3 local and systemic injection reactions, compared to 52.6% and 63.2% for Shingrix, respectively [1] Group 3: Future Plans - The second part of the Phase I/II trial will include adults aged 70 and older, with an expected launch in the second half of 2025 [1]